Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06719583 · ClinicalTrials.gov registry record

Black and African Americans Connections to Parkinson's Disease (BLAAC PD)

A clinical trial of Parkinson Disease, sponsored by Michael J. Fox Foundation for Parkinson's Research.

Recruiting
Registry status
2,000
Enrollment target
12
Study locations

NCT06719583: Recruiting study of Parkinson Disease, sponsored by Michael J. Fox Foundation for Parkinson's Research.

NCT06719583 is a study of Parkinson Disease that is actively recruiting participants, run by Michael J. Fox Foundation for Parkinson's Research. The registered enrollment target is 2,000 participants, below the 5,320-participant average among 297 other Parkinson Disease trials with a reported enrollment target (62% lower). The trial reports 12 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06719583, a study of Parkinson Disease, is actively recruiting participants, sponsored by Michael J. Fox Foundation for Parkinson's Research.

RECRUITING
Registry status
2,000 participants
Enrollment target
12
Study locations

Study Summary

BLAAC PD is a research study to understand what Parkinson's disease looks like for Black and African American communities. BLAAC PD is happening at research centers around the United States. The study is part of the Global Parkinson's Genetics Program (GP2). GP2 is a research project working to transform understanding of the genetics of Parkinson's disease and make that knowledge globally relevant.

Primary Outcome

To explore novel risk factors and characterization of known genetic risk factors contributing to Parkinson's disease risk in the Black and African American population.

Conditions Studied

Study Locations (12)

Illinois

  • Rush University - Chicago
  • University of Chicago - Chicago

Louisiana

  • Ochsner Clinic Foundation - New Orleans
  • Louisiana State University Health Sciences Center Shreveport - Shreveport

Maryland

  • University of Maryland - Baltimore
  • Kaiser Permanente Midatlantic States - Rockville

Alabama

  • University of Alabama at Birmingham - Birmingham

Florida

  • University of Florida - Gainesville

Missouri

  • Washington University in St. Louis - St Louis

Ohio

  • University Hospitals Cleveland Medical Center - Cleveland

South Carolina

  • Medical University of South Carolina - Charleston

Trial Details

FieldValue
Enrollment Target 2,000 participants
Start Date 2020-11-16
Est. Completion 2027-12-31

What NCT06719583 shows while recruiting

NCT06719583 is an observational study that tracks outcomes without assigning an intervention. Its 2,000 participants enrollment target places it among the larger protocols in the corpus, below the 5,320-participant average among 297 other Parkinson Disease trials with a reported enrollment target (62% lower).

The record links to 1 condition, with Parkinson Disease appearing as the primary indexed condition, and to 0 interventions.

NCT06719583 lists 12 locations in 9 states (Illinois, Louisiana, Maryland).

Frequently Asked Questions

What is clinical trial NCT06719583 about?

NCT06719583 is a clinical study titled "Black and African Americans Connections to Parkinson's Disease (BLAAC PD)". BLAAC PD is a research study to understand what Parkinson's disease looks like for Black and African American communities. BLAAC PD is happening at research centers around the United States. The study is part of the Global Parkinson's Genetics Program (GP2). GP2 is a research project working to tra...

What is the current status of trial NCT06719583?

This trial is currently recruiting. The enrollment target is 2,000 participants. The study started on 2020-11-16. Estimated completion is 2027-12-31.

What conditions does trial NCT06719583 study?

This clinical trial studies the following conditions: Parkinson Disease.

Who is sponsoring clinical trial NCT06719583?

This trial is sponsored by Michael J. Fox Foundation for Parkinson's Research, which has 14 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06719583 being conducted?

This trial has 12 study locations across Alabama, Florida, Illinois, Louisiana, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Parkinson Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06719583's enrollment target sits among peer trials

2,000 10th of 297 higher than 287 of 297 other Parkinson Disease trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Parkinson Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00001465 · 2,000 participants

    Study of the Disease Process of Lymphangioleiomyomatosis

  • NCT00001595 · 2,000 participants

    An Investigation of Pituitary Tumors and Related Hypothalmic Disorders

  • NCT00138931 · 2,000 participants

    Genetics of Cardiovascular and Neuromuscular Disease

  • NCT00288119 · 2,000 participants

    Genetic Determinants of Barrett's Esophagus and Esophageal Adenocarcinoma

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06719583, the US trial registry maintained by the National Library of Medicine. NCT06719583 (large enrollment · multi site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.